PAH Treatment Transition to Selexipag With Tolerability-Based Titration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary arterial hypertension (PAH) often fail to halt disease progression, leading to severe symptoms and potential lung transplantation, necessitating alternative therapeutic approaches.
Innovation Solution
Transitioning patients from non-selexipag prostacyclin pathway agents to selexipag by administering a starting dose and gradually increasing to a highest tolerable maintenance dose, maintained for at least 14 days without interruption, while considering individual patient tolerability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If patients continue taking non-selexipag prostacyclin pathway agents, then disease progression may be halted initially, but treatment efficacy diminishes over time and alternative approaches are needed
Solution Approach 1:
The patent applies parameter changes by transitioning patients from one prostacyclin pathway agent (non-selexipag) to a different agent (selexipag) with potentially different pharmacokinetic and pharmacodynamic parameters. This switch allows for renewed treatment efficacy by introducing a new drug with distinct characteristics while maintaining the same therapeutic pathway, thereby addressing the diminishing returns of long-term monotherapy.
2Reliability
If selexipag dose is increased to highest tolerable maintenance dose, then treatment efficacy is improved, but patient tolerability may be compromised
Solution Approach 1:
The patent implements dynamics through flexible dose adjustment strategies where the selexipag dose is titrated to the highest tolerable maintenance dose. This dynamic approach allows the treatment regimen to adapt to individual patient responses and tolerability, optimizing efficacy while managing adverse effects by adjusting the dose level rather than using a fixed dosing protocol.
Solution Approach 2:
The patent employs feedback mechanisms by monitoring patient tolerability and adverse effects during dose escalation to determine the highest tolerable maintenance dose. This feedback loop allows clinicians to adjust the selexipag dose based on patient response, balancing treatment efficacy with acceptable tolerability by continuing to increase the dose only as long as the patient can tolerate it.
3Ease of operation
If patients stop non-selexipag PPA less than 7 days before selexipag initiation, then transition is simplified, but risk of withdrawal symptoms or disease flare may increase
Solution Approach 1:
The patent applies preliminary action by recommending that patients stop their non-selexipag prostacyclin pathway agent within a specific timeframe (less than 7 days) before initiating selexipag. This preliminary discontinuation allows for a smoother transition by avoiding drug interactions and ensuring that the patient is ready to receive the new medication, thereby simplifying the transition process while maintaining safety through defined timing parameters.
Data Source
AI summary
The present disclosure provides methods of transitioning a patient being treated for pulmonary arterial hypertension with a non-selexipag prostacyclin pathway agent (PPA) to selexipag.